# US 2023/0405075 A1 · Preparations containing mitragyne extract or its isolated alkaloids and cannabis extract or its isolated cannabinoids, and cosmetic and/or pharmaceutical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405075 A1
- Document ID: US20230405075A1
- Status: Published application
- Kind: A1
- Application number: 18/024,788
- Filed: 2020-07-08
- Published: 2023-12-21
- Earliest claimed: 2020-07-08
- Assignees: Herba Invest, Pte. Ltd.
- Applicants: Herba Invest, Pte. Ltd.
- Inventors: Giancarlo CRAVOTTO
- Web page: https://patentgrep.com/patent/US20230405075A1

## CPC

- A61K 36/74: Rubiaceae (Madder family)
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 36/3482: {Cannabis}
- A61P 17/06: Antipsoriatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A cosmetic and pharmaceutical preparation for topical use contains from about 0.00001 wt.-% to about 20 wt.-%, of one or more alkaloids of Mitragyna speciosa and from about 0.00001 wt.-% to about 20 wt.-% of one or more cannabinoids of Cannabis indica or Cannabis sativa. The preparation is intended for use in preventing and/or treating skin and mucosal disorders and conditions.

## Claims

### Claim 1

A cosmetic and pharmaceutical preparation for topical or inhalatory use containing one or more alkaloids of Mitragyna speciosa and one or more cannabinoids of Cannabis indica or Cannabis sativa, wherein the preparation contains at most 20 wt.-%, of said one or more alkaloids and at most 20 wt.-%, of said one or more cannabinoids.

### Claim 2 (depends on 1)

The preparation as claimed in claim 1, containing from about 0.00001 wt.-% to about 20 wt.-% of said one or more alkaloids, and from about 0.00001 wt.-% to about 20 wt.-% of one or more cannabinoids, the weight percentages being related to the total amount of the preparation.

### Claim 3 (depends on 1)

The preparation as claimed in claim 1, wherein said one or more alkaloids and said one or more cannabinoids are present as purified extracts of Mitragyna speciosa and a Cannabis indica or Cannabis sativa, respectively, or are present as isolated alkaloids and cannabinoids, respectively.

### Claim 4 (depends on 1)

The preparation as claimed in claim 1, wherein said one or more alkaloids are selected from: speciociliatine (SC), 3-isopaynantheine (IP), speciogynine (SG), paynantheine (P) and mitragynine (MG); and said one or more cannabinoids are selected from Δ(9)-tetrahydrocannabinol (THC), cannabidiol (CBD), tetrahydro-cannabinolic acid (THCA) and cannabidiolic acid (CBDA).

### Claim 5 (depends on 1)

The preparation as claimed in claim 1, further containing an enhancer or ethosomal carrier for improving transdermal permeation of more lipophilic alkaloids and cannabinoids.

### Claim 6 (depends on 1)

The preparation as claimed in claim 1, having a dosage form selected from ointment, O/W-emulsion, W/O-emulsion, dispersion, lotion, gel, mousse, tincture, spray, aerosol, foam, powder, tape and patch.

### Claim 7 (depends on 1)

A method of preventing and/or treating skin and mucosal disorders and/or conditions or disorders and/or conditions of the respiratory tract, comprising the step of using the preparation according to claim 1.

### Claim 8 (depends on 7)

The method as claimed in claim 7, wherein said skin disorders and/or conditions include ageing and redness, inflammation, acne, atopic dermatitis, psoriasis, couperose, dandruff, scalp disorders, excessive sweating (hyperhidrosis), pruritus and sub-cutaneous pain.

### Claim 9 (depends on 7)

The method as claimed in claim 7, wherein said mucosal disorders and/or conditions include lip disorders, rhagades and haemorrhoids.

### Claim 10 (depends on 7)

The method as claimed in claim 7, wherein said disorders and/or conditions of the respiratory tract include sinusitis, adenoiditis, laryngitis, nasopharyngitis, chronic rhinitis, chronic pharyngitis and tracheitis, bronchiolitis and bronchitis.

### Claim 11 (depends on 7)

The method as claimed in claim 7, wherein said preparation is used in a dosage form for topical or inhalatory administration.

### Claim 12 (depends on 11)

The method as claimed in claim 11, wherein said preparation is used in a dosage form for topical administration in combination with a dosage form for systemic administration.

### Claim 13 (depends on 1)

A method of treating a human being suffering from skin and mucosal disorders and/or diseases and/or conditions, comprising topical and/or inhalatory administration of the preparation as claimed in claim 1.

### Claim 14 (depends on 13)

A method according to claim 13, including topical or inhalatory administration of the preparation combined with a systemic administration.

### Claim 15 (depends on 2)

The preparation according to claim 2, containing from about 0.0001 wt.-% to about 10 wt.-% of said one or more alkaloids.

### Claim 16 (depends on 2)

The preparation according to claim 2, containing from about 0.0001 wt.-% to about 10 wt.-% of one or more cannabinoids.

### Claim 17 (depends on 2)

The preparation according to claim 2, containing from about 0.1 wt.-% to about 5 wt.-% of said one or more alkaloids.

### Claim 18 (depends on 2)

The preparation according to claim 2, containing from about 0.1 wt.-% to about 5 wt.-% of one or more cannabinoids.

### Claim 19 (depends on 1)

The preparation according to claim 1, further containing an enhancer or ethosomal carrier for improving transdermal permeation of mitragynine (MG) and tetrahydrocannabinol (THC).
